

## COMPANY PROFILE



**Martina Kröner**

Managing Director, SVP Corp. Dev.  
Martina.kroener@synteract.com

## History and Mission

**Synteract** is an innovative CRO supporting biopharma companies in all phases of clinical development to bring new medicines to market. Synteract has conducted 4,000+ studies in 60+ countries, contributing to more than 240 product approvals. We offer notable expertise in dermatology, oncology, pediatrics, neuro degenerative, and rare & orphan indications.

## Highlights

“Bringing Clinical Trials to Life” is not simply our tagline, it’s a promise that is foundational to what we do on behalf of clients each day, because patients are waiting. At Synteract, we are focused on supporting innovation in drug development, and advancement of better therapies in healthcare to improve patients’ lives. As your contract research organization, we listen and collaborate to tailor a project plan that strategically adapts our services to support your specific project needs. Whether needed for a global, full-service offering, a standalone service like Biostats or Safety Services, functional service provision of resources, or consulting, our teams of experts are here to help.



**Synteract GmbH**  
Albrechtstr. 14  
80636 Munich, Germany

Tel. +49 89 12 66 80 0  
Fax +49 89 12 66 80 2444

BVMA member since 1996  
Audits passed in 2000, 2003, 2006,  
2009, 2012, 2015 and 2018



[www.synteract.com](http://www.synteract.com)

## Services

### Oncology

- Synteract has managed 160+ oncology trials in the past 5 years in complex treatments like pathway-targeted therapies, chemotherapy, immunotherapy, cell-based and gene therapies.
- We were on of the first CROs to work in immunotherapy over 10 years ago.

### Pediatrics

- We’ve conducted 310+ pediatric clinical trials globally, in 25+ indications.
- Our pediatric cross-functional team helps clients navigate complex research to allow medicines to serve the littlest ones.

### Dermatology

- As leading dermatology CRO, we support novel and in-demand dermatology drug development.
- We’ve conducted 270+ derm trials, in 30+ indications of dermatologic disease and skin care products.

### Neuro Degenerative

- We’ve managed 130+ neuro degenerative trials in the past 5 years, with extensive experience in drugs addressing Alzheimer’s, Parkinson’s, ALS, MS, migraine, schizophrenia, more.

### Rare & Orphan

- We’ve conducted 130+ trials in rare and orphan diseases in the past 5 years alone. We specialize in unique studies that affect a small portion of the population or are otherwise “forgotten” by other treatments.